Navigation Links
For Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabThera's Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
Date:8/30/2010

BURLINGTON, Mass., Aug. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.

The new European Physician & Payer Forum report entitled Will Emerging MAbs Threaten MabThera's Domination of the Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Markets in Europe? Clinician and Payer Perspectives finds that sales of MabThera, which was first marketed more than a decade ago, continue to dwarf those of more recently launched monoclonal antibodies (MAbs) such as Genzyme's MabCampath and Bayer's Zevalin. When asked what safety/toxicity improvements over MabThera would carry the most weight in convincing prescribers to switch from MabThera to a novel MAb, the largest group of surveyed clinicians in France, Germany, Italy, Spain and the United Kingdom (EU5) cite concern about the rate of infections, although many are satisfied with the safety of MabThera.

"Thirty seven percent of surveyed European hematologist-oncologists say that an improvement in the rate of infections would carry the most weight, while 20 percent of surveyed clinicians cite concern about the rate of neutropenia," said Decision Resources Analyst Andrew Merron, Ph.D. "However, more than one-quarter of surveyed European hematologist-oncologists say that all side effects associated with MabThera are manageable."

The report also finds that emerging MAbs will not only face competition from MabThera in the EU5 markets but also from biosimilar rituximab. In the United Kingdom, interviewed payers expect that biosimilars will be used in preference to the brand if the price differences are favorable and efficacy/safety are the same as the brand.

The report is based on a survey of 251 hematologist-oncologists from Germany (52), France (50), Italy (49), Spain (50) and the United Kingdom (50) and interviews with 15 European payers from Germany (3), France (3), Italy (3), Spain (3) and the United Kingdom (3).

WebinarMedia members are welcome to attend our upcoming webinar based on this report entitled European Clinician and Payer Perspectives on the Dominance of Roche's MabThera in NHL and CLL – Will Emerging Monoclonal Antibodies Be Able to Compete? This online presentation will be held on September 22, 2010 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at ccomfort@dresources.com.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 16, 2017 The ... Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), ... Surface Coatings & Paints), Region - Global ... market was valued at USD 4.51 Billion ... USD 6.41 Billion by 2021, at a ...
(Date:1/16/2017)... 2017  Dovetail Genomics today announced the commercial launch ... which yields chromosome-scale genome assemblies. The service is available ... on Jan. 17 at the Plant & Animal Genome ... . "We are thrilled to be expanding ... Dovetail Hi-C offering," said Todd Dickinson , Dovetail,s ...
(Date:1/15/2017)... January 16, 2017 Der Vorstand ... für die Regeneration des menschlichen Gewebes, gibt die Ernennung ... sofortiger Wirkung bekannt. ... Bill Allan ist ... bekleidete eine Reihe von Geschäftsführer- und anderen Führungspositionen bei ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go ... delivered straight to your door for a romantic, lobster feast in the comfort of ... for Valentine's Day. The dinners will be featured until February 15th, 2017. , ...
(Date:1/15/2017)... NJ (PRWEB) , ... January 15, 2017 , ... ... firm located in Montclair, NJ is pleased to announce that it will be ... is located in Montclair and Glen Ridge townships, servicing all surrounding towns. The ...
(Date:1/14/2017)... ... January 13, 2017 , ... According to a ... Mediterranean diet may lower the risk of type 2 diabetes, Alzheimer’s, and cardiovascular ... health and wellness benefits linked to a Mediterranean diet are only some of ...
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating ... mask effect in Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... a unique freeze frame transition from one clip to the next. , To ...
(Date:1/13/2017)... , ... January 13, 2017 , ... The 18th European ... America hotel on March 3-4, 2017. This Congress is expertly designed to meet ... management of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor ...
Breaking Medicine News(10 mins):